{"id":"tv-46000","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TV-46000 is a selective inhibitor of the sodium-activated potassium channel, Nav1.5, which plays a key role in the pathophysiology of atrial fibrillation. By inhibiting this channel, TV-46000 is expected to reduce the frequency of atrial fibrillation episodes and improve symptoms.","oneSentence":"TV-46000 is a small molecule in development for the treatment of atrial fibrillation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:16.028Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT03503318","phase":"PHASE3","title":"Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2018-04-27","conditions":"Schizophrenia","enrollment":544},{"nctId":"NCT03893825","phase":"PHASE3","title":"A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2019-04-17","conditions":"Schizophrenia","enrollment":336}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Risperidone"],"phase":"phase_3","status":"active","brandName":"TV-46000","genericName":"TV-46000","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TV-46000 is a small molecule in development for the treatment of atrial fibrillation. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}